EDX Medical to lead Scottish Prostate Cancer Testing Initiative

EDX

EDX Medical Group plc (AQSE:EDX), which develops innovative digital diagnostic products and services supporting personalised treatments for cancer, cardiovascular and infectious diseases, has announced that the Company is to be the primary delivery partner in the Scottish Prostate Cancer Initiative, a new project which aims to improve the early detection and diagnosis of the disease.

The Initiative has been launched at the Royal Glasgow of Physicians and Surgeons in Glasgow by Olympian Sir Chris Hoy, Scottland rugby internationalist, Kenny Logan, Sir Tom Hunter and Professor Sir Chris Evans, founder of EDX Medical.

Major employers and organisations from various sectors are supporting the Initiative.

Throughout this year, EDX Medical will provide diagnostic tests and laboratory services to the Initiative which will offer 25,000 men across Scotland aged between 40 and 80 free PSA testing.

Each man who participates in the Initiative will be asked to give a simple blood sample to measure Prostate-Specific Antigen (PSA) levels. In addition, a range of more advanced diagnostic tests will be deployed across selected groups of men to help develop a greater understanding of the role of genetic risk and the significance of other biochemical markers in the origins of prostate cancer.

The aim of the study is to explore how the existing clinical pathway for detecting and treating prostate cancer can be improved.

The not-for-profit Initiative is supported by a range of organisations and employers across Scotland and findings from the study will be made available to NHS Scotland.

Organisations supporting the project include the Scottish Police Federation, Glasgow Credit Union and Dundee City Council. Employers include businessmen Sandy and James Easdale and McGill’s Buses, The Arnold Clark Group, The Malcolm Group, Lord Haughey and City Facilities Management. Inverness Caledonian Thistle and St Johnstone Football Clubs will be hosting testing events at their stadiums.

EDX Medical is delivering the Initiative in conjunction with the Graham Fulford Charitable Trust, a prostate health awareness charity. A pilot programme was completed in February and early March in the West of Scotland with the support of employers. More than 1400 men underwent tests in a week.

Professor Sir Chris Evans, OBE, founder of EDX Medical, said: “This Initiative has tremendous potential to save lives and heralds a new era for prostate cancer diagnosis and EDX Medical is proud to be playing a leading role in the delivery of the project.

“Testing 25,000 men is a big challenge but we’re delighted that so many employers and organisations have rallied round. We hope that many more will also join us in promoting the Initiative in the months ahead. We had a fantastic, positive response to the pilot programme and we hope that enthusiasm will be carried across all of Scotland.”

We’ll keep you in the loop!

Join 1,000's of investors who read our articles first

We don’t spam! Read our privacy policy for more info.

Share on:
Find more news, interviews, share price & company profile here for:

Latest Company News

EDX Medical backs large-scale prostate cancer testing in Scotland

EDX Medical is supporting a Scottish prostate cancer testing programme for 25,000 men, strengthening its position in early cancer detection and practical diagnostic services.

AIM admission marks new phase for EDX Medical’s diagnostic expansion

EDX Medical has joined AIM as it advances the commercial rollout of diagnostic tests targeting cancer and other major diseases, supported by growing clinical screening programmes.

EDX Medical targets AIM growth with ultra-accurate cancer diagnostics

EDX Medical Chief Scientific Officer Professor Chris Evans discusses the company’s AIM admission, prostate cancer testing programme in Scotland, and plans to commercialise a range of advanced diagnostic tests.

EDX Medical begins trading on AIM following move from Aquis

EDX Medical has commenced trading on the AIM market of the London Stock Exchange under the ticker EDX, highlighting its growth strategy in cancer and infectious disease diagnostics and its expanding portfolio of personalised healthcare technologies.

EDX Medical seeks AIM admission as it prepares to leave Aquis

EDX Medical has announced plans to transfer its ordinary shares from the Aquis Stock Exchange to AIM, with admission and withdrawal expected to take effect simultaneously on 13 May 2026. The company says the move is intended to improve access to growth capital, investor visibility and share liquidity.

EDX Medical to lead Scottish Prostate Cancer Testing Initiative

EDX Medical will serve as the primary delivery partner for the Scottish Prostate Cancer Initiative, which plans to offer free PSA testing to 25,000 men across Scotland and explore ways to improve early detection and diagnosis of the disease.

Search